Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives

Whi-An Kwon, Min-Kyung Lee · 2025

Read Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives by Whi-An Kwon, Min-Kyung Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640162.txt.

Description

Kwon and Lee reviewed first-line treatment for advanced bladder cancer in this paper from twenty twenty-four. The cancer, metastatic urothelial carcinoma, has long been treated first with cisplatin-based chemotherapy. Up to half of patients, though, cannot take cisplatin because of other health problems. Immune checkpoint drugs filled part of that gap but left survival poor.

A newer pairing changed the picture. Enfortumab vedotin plus pembrolizumab beat chemotherapy on both survival and time without growth. The pair is now an option for patients who cannot take cisplatin. Platinum chemotherapy still matters for many patients. The review walks through current choices and coming strategies to guide doctors at the front line.

Catalog record

CREATORWhi-An Kwon, Min-Kyung Lee
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11640162

Browse the full library · About the Tower of Babel